PATENT ABSTRACTS 511

5114710

M - C S F AS A T H E R A P E U T I C A G E N T F O R

T H R O M B O C Y T O P E N I A

city, and highly effective for protecting infection by any of the serotypes of Pseudomonas aeruginosa. PSC-A can be used as the active component in a pharmaceutical agent for pro- tecting Pseudomonas aeruginosa infection.

Fumimaro Takaku, Kazuo Motoyoshi, Tokyo, Japan assigned to Green Cross Corporation; Morinaga Milk Industry Co Ltd

A therapeutic agent for thrombocytopenia due to hemopoietic disorder induced by various causes comprises as an active ingredient a specific human monocytemacrophage colony stimulating factor. It is administered for the treatment and/or prevention of such throm- bocytopenia.

5114711

C O V A L E N T L Y L I N K E D P O L Y P E P T I D E C E L L

M O D U L A T O R S S U C H AS I N T E R F E R O N - L Y M P H O T O X I N

C O N J U G A T E S

Leslie D Bell, Keith McCullagh, Alan Porter, Thame, United Kingdom assigned to G D Searle & Co

Described is a new class of polypeptide cell modulators characterized by being composed of two covalently linked cell modulators in a linear polypeptide sequence, Such dual function poly- peptides have new and particularly useful ac- tivities when the component polypeptide cell modulators are interferons, lymphokines or cytotoxins which act through different and specific cell receptors to initiate complementary biological activities.

5114712

C O M M O N A N T I G E N ( P S C - A ) T O P S E U D O M O N A S A E R U G I N O S A

W H I C H A C T S AS A N A G E N T F O R P R O T E C T I N G P S E U D O M O N A S

A E R U G I N O S A I N F E C T I O N

Tamots Fukuda, Shiro Shigeta, Hiroaki Okuya, Yasuyuki Kuroiwa, Tadashi Sudo, Chiba, Japan assigned to Mitsui Toatsu Chemicals Inc

PSC-A is a new serological common antigen to Pseudomonas aeruginosa having very low toxi-

5114713

P. F A L C I P A R U M C S - P E P T I D E S AS U N I V E R S A L T - C E L L E P I T O P E

Francesco Sinigaglia, Basel, Switzerland as- signed to Hoffmann-La Roche Inc

The present invention relates to the use of a pep- tide from the circumsporozoite (CS) protein of Plasmodium falciparum (P. faiciparum) and the derivatives thereof as a universally recognized T- cell epitope i.e. an epitope which is recognized in association with many different human and mouse major histocompatibility complex (MHC) haplotypes e.g. in the context of the human MHC class II molecules such as DRI, DR2, DR4, DR5, DRw6, DR7 or DR9. Fur- thermore the present invention relates to the above-mentioned peptide per se and to immuno- genic compositions comprising such a peptide or a derivative thereof. These immunogenic com- positions can be used as vaccines to elicit a durable immune response against a pathogenic agent in humans and animals irrespective of the MHC haplotype of the host.

5114721

P R E P A R A T I O N O F T - C E L L A N D T - C E L L M E M B R A N E F O R U S E I N P R E V E N T I O N A N D T R E A T M E N T

O F A U T O I M M U N E D I S E A S E S

Irun Cohen, Meir Shinitzky, Richard L Edelson, Rehovot, Israel assigned to Yeda Research and Development Co Ltd

Pharmaceutical preparations are provided for preventing or treating autoimmune diseases in which the active principle is activated T- lymphocyte cells, specific for the autoimmune disease to be treated, which cells have been treated by incubation with a photoactivatable psoralen cross-linking agent, such as 8- methoxypsoralen, and then photoactivated. The active principle may also be the membrane frac- tion of such cells. Such preparations may be for- mulated into pharmaceutical compositions and administered to prevent or treat autoimmune disesases.